Cargando…

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Evidence available on the effectiveness and costs of biological therapies for the initial treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a population-based cohort investigation for assessing overall survival and costs associated with their use in a real-worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Matteo, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Corrao, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226266/
https://www.ncbi.nlm.nih.gov/pubmed/32244478
http://dx.doi.org/10.3390/cancers12040839
_version_ 1783534250559012864
author Franchi, Matteo
Garau, Donatella
Kirchmayer, Ursula
Di Martino, Mirko
Romero, Marilena
De Carlo, Ilenia
Scondotto, Salvatore
Corrao, Giovanni
author_facet Franchi, Matteo
Garau, Donatella
Kirchmayer, Ursula
Di Martino, Mirko
Romero, Marilena
De Carlo, Ilenia
Scondotto, Salvatore
Corrao, Giovanni
author_sort Franchi, Matteo
collection PubMed
description Evidence available on the effectiveness and costs of biological therapies for the initial treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a population-based cohort investigation for assessing overall survival and costs associated with their use in a real-world setting. Healthcare utilization databases were used to select patients newly diagnosed with mCRC between 2010 and 2016. Those initially treated with biological therapy (bevacizumab or cetuximab) added to chemotherapy were propensity-score-matched to those treated with standard chemotherapy alone, and were followed up to June 30th, 2018. Kaplan–Meier survival estimates, restricted mean survival time (RMST) and cumulative costs were compared between the two treatment arms. The study cohort included 1896 mCRC patients treated with biological therapy matched to 5678 patients treated with chemotherapy alone. Median overall survival was 21.8 and 20.2 months, respectively. After 84 months of follow-up, RMSTs were 30.9 and 31.9 months (p = 0.193), indicating no differences between the average survival time between treatment arms. Patients treated with biological therapy were associated with higher costs. Cumulative per capita costs were €59,663 and €44,399, respectively. In our study, first-line biological therapy did not improve long-term overall survival and was associated with higher costs as compared to standard chemotherapy.
format Online
Article
Text
id pubmed-7226266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72262662020-05-18 Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project Franchi, Matteo Garau, Donatella Kirchmayer, Ursula Di Martino, Mirko Romero, Marilena De Carlo, Ilenia Scondotto, Salvatore Corrao, Giovanni Cancers (Basel) Article Evidence available on the effectiveness and costs of biological therapies for the initial treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a population-based cohort investigation for assessing overall survival and costs associated with their use in a real-world setting. Healthcare utilization databases were used to select patients newly diagnosed with mCRC between 2010 and 2016. Those initially treated with biological therapy (bevacizumab or cetuximab) added to chemotherapy were propensity-score-matched to those treated with standard chemotherapy alone, and were followed up to June 30th, 2018. Kaplan–Meier survival estimates, restricted mean survival time (RMST) and cumulative costs were compared between the two treatment arms. The study cohort included 1896 mCRC patients treated with biological therapy matched to 5678 patients treated with chemotherapy alone. Median overall survival was 21.8 and 20.2 months, respectively. After 84 months of follow-up, RMSTs were 30.9 and 31.9 months (p = 0.193), indicating no differences between the average survival time between treatment arms. Patients treated with biological therapy were associated with higher costs. Cumulative per capita costs were €59,663 and €44,399, respectively. In our study, first-line biological therapy did not improve long-term overall survival and was associated with higher costs as compared to standard chemotherapy. MDPI 2020-03-31 /pmc/articles/PMC7226266/ /pubmed/32244478 http://dx.doi.org/10.3390/cancers12040839 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Franchi, Matteo
Garau, Donatella
Kirchmayer, Ursula
Di Martino, Mirko
Romero, Marilena
De Carlo, Ilenia
Scondotto, Salvatore
Corrao, Giovanni
Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
title Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
title_full Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
title_fullStr Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
title_full_unstemmed Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
title_short Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
title_sort effectiveness and costs associated to adding cetuximab or bevacizumab to chemotherapy as initial treatment in metastatic colorectal cancer: results from the observational fabio project
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226266/
https://www.ncbi.nlm.nih.gov/pubmed/32244478
http://dx.doi.org/10.3390/cancers12040839
work_keys_str_mv AT franchimatteo effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT garaudonatella effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT kirchmayerursula effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT dimartinomirko effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT romeromarilena effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT decarloilenia effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT scondottosalvatore effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject
AT corraogiovanni effectivenessandcostsassociatedtoaddingcetuximaborbevacizumabtochemotherapyasinitialtreatmentinmetastaticcolorectalcancerresultsfromtheobservationalfabioproject